ub.xmlui.mirage2.page-structure.muninLogoub.xmlui.mirage2.page-structure.openResearchArchiveLogo
    • EnglishEnglish
    • norsknorsk
  • Velg spraaknorsk 
    • EnglishEnglish
    • norsknorsk
  • Administrasjon/UB
Vis innførsel 
  •   Hjem
  • Det helsevitenskapelige fakultet
  • Institutt for klinisk medisin
  • Artikler, rapporter og annet (klinisk medisin)
  • Vis innførsel
  •   Hjem
  • Det helsevitenskapelige fakultet
  • Institutt for klinisk medisin
  • Artikler, rapporter og annet (klinisk medisin)
  • Vis innførsel
JavaScript is disabled for your browser. Some features of this site may not work without it.

Menopausal hormone therapy and breast cancer risk: effect modification by body mass through life

Permanent lenke
https://hdl.handle.net/10037/14971
DOI
https://doi.org/10.1007/s10654-018-0431-7
Thumbnail
Åpne
article.pdf (237.7Kb)
Accepted manuscript version (PDF)
Revised Tables.pdf (61.89Kb)
Accepted manuscript version (PDF)
Online Material 2.pdf (133.9Kb)
Accepted manuscript version (PDF)
Online Material.pdf (43.94Kb)
Accepted manuscript version (PDF)
Revised Tables_2.pdf (64.65Kb)
Accepted manuscript version (PDF)
Dato
2018-08-06
Type
Journal article
Tidsskriftartikkel
Peer reviewed

Forfatter
Sandvei, Marie Søfteland; Vatten, Lars Johan; Bjelland, Elisabeth Krefting; Eskild, Anne; Hofvind, Solveig; Ursin, Giske; Opdahl, Signe
Sammendrag
It is not known whether increased breast cancer risk caused by menopausal hormone therapy (HT) depends on body mass patterns through life. In a prospective study of 483,241 Norwegian women aged 50–69 years at baseline, 7656 women developed breast cancer during follow-up (2006–2013). We combined baseline information on recalled body mass in childhood/adolescence and current (baseline) body mass index (BMI) to construct mutually exclusive life-course body mass patterns. We assessed associations of current HT use with breast cancer risk according to baseline BMI and life-course patterns of body mass, and estimated relative excess risk due to interaction (RERI). Within all levels of baseline BMI, HT use was associated with increased risk. Considering life-course body mass patterns as a single exposure, we used women who “remained at normal weight” through life as the reference, and found that being “overweight as young” was associated with lower risk (hazard ratio (HR) 0.85, 95% confidence interval (CI) 0.76–0.94), whereas women who “gained weight” had higher risk (HR 1.20, 95% CI 1.12–1.28). Compared to never users of HT who were “overweight as young”, HT users who either “remained at normal weight” or “gained weight” in adulthood were at higher risk than expected when adding the separate risks (RERI 0.52, 95% CI 0.09–0.95, and RERI 0.37, 95% CI − 0.07–0.80), suggesting effect modification. Thus, we found that women who remain at normal weight or gain weight in adulthood may be more susceptible to the risk increasing effect of HT compared to women who were overweight as young.
Beskrivelse
Accepted manuscript version. Published version available at https://doi.org/10.1007/s10654-018-0431-7.
Forlag
Springer
Sitering
Sandvei, M.S., Vatten, L.J., Bjelland, E.K., Eskild, A., Hofvind, S., Ursin, G. & Opdahl, S. (2018). Menopausal hormone therapy and breast cancer risk: effect modification by body mass through life. European Journal of Epidemiology. https://doi.org/10.1007/s10654-018-0431-7
Metadata
Vis full innførsel
Samlinger
  • Artikler, rapporter og annet (klinisk medisin) [1974]

Bla

Bla i hele MuninEnheter og samlingerForfatterlisteTittelDatoBla i denne samlingenForfatterlisteTittelDato
Logg inn

Statistikk

Antall visninger
UiT

Munin bygger på DSpace

UiT Norges Arktiske Universitet
Universitetsbiblioteket
uit.no/ub - munin@ub.uit.no

Tilgjengelighetserklæring